Acute respiratory distress syndrome (ARDS) is a devastating hypoxemic respiratory failure, characterized by disruption of the alveolar-capillary membrane barrier. Current management for ARDS remains supportive, including lung-protective ventilation and a conservative fluid strategy. Mesenchymal stem cells (MSCs) have emerged as a potentially attractive candidate for the management of ARDS through facilitating lung tissue regeneration and repair by releasing paracrine soluble factors. Over the last decade, a variety of strategies have emerged to optimize MSC-based therapy. Among these, the strategy using genetically modified MSCs has received increased attention recently due to its distinct advantage, in conferring incremental migratory capacity and, enhancing the anti-inflammatory, immunomodulatory, angiogenic, and antifibrotic effects of these cells in numerous preclinical ARDS models, which may in turn provide additional benefits in the management of ARDS. Here, we provide an overview of recent studies testing the efficacy of genetically modified MSCs using preclinical models of ARDS.

中文翻译：

---

转基因间充质干细胞治疗急性呼吸窘迫综合征。


急性呼吸窘迫综合征（ARDS）是一种毁灭性的低氧性呼吸衰竭，其特征是肺泡毛细血管膜屏障破坏。目前对 ARDS 的治疗仍然是支持性的，包括肺保护性通气和保守的液体策略。间充质干细胞（MSC）通过释放旁分泌可溶性因子促进肺组织再生和修复，已成为治疗 ARDS 的潜在有吸引力的候选者。在过去的十年中，出现了多种策略来优化基于间充质干细胞的治疗。其中，使用转基因间充质干细胞的策略最近因其独特的优势而受到越来越多的关注，即赋予增量迁移能力，并在许多临床前 ARDS 模型中增强这些细胞的抗炎、免疫调节、血管生成和抗纤维化作用。反过来可能会为 ARDS 的管理提供额外的好处。在这里，我们概述了最近使用 ARDS 临床前模型测试转基因 MSC 功效的研究。